Progression rate of myelopathy in X-linked adrenoleukodystrophy heterozygotes

Autor: Ursula da Silveira Matte, Clarissa Troller Habekost, Pedro Schestatsky, Carmen Regla Vargas, Laura Bannach Jardim, Vitor Rocco Torrez, Luis Valmor Cruz Portela, Daniella de Moura Coelho, Vitor Torres Felix, Jean Pierre Oses, Vanessa Leotti Torman, Fernanda dos Santos Pereira
Rok vydání: 2015
Předmět:
Zdroj: Metabolic Brain Disease. 30:1279-1284
ISSN: 1573-7365
0885-7490
Popis: X-linked adrenoleukodystrophy heterozygote women can present adult onset myeloneuropathy and little is known about its natural history. We aimed to describe the progression rate of the neurological impairment in the prospective follow-up of our cohort and to look for prognostic factors. The neurological scales Japanese Orthopaedic Association (JOA) and Severity Score System for Progressive Myelopathy (SSPROM) were applied at baseline in 29 symptomatic carriers and in follow-up visits. Age at onset, disease duration, X inactivation pattern, determination of the allele expressed, plasma levels of the very long chain fatty acids and of the neuron-specific enolase, and somato-sensory evoked potentials, were taken at baseline. The slope of the linear regression of both JOA and SSPROM versus disease duration since the first symptom was estimated using mixed modeling. JOA and SSPROM decreased 0.42 and 1.87 points per year, respectively (p < 0.001). None of the parameters under study influenced these rates. We estimated that the number of carriers per arm needed in a future 12 month trial with 80 % power and a 50 % reduction in disease progression would be 225 women for JOA and 750 for SSPROM. The progression rates of the studied neurological scales were small, did not depend on any modifier factor known, and reflected the characteristically slow worsening of symptoms in X-ALD heterozygotes. Better biomarkers are still necessary for future studies.
Databáze: OpenAIRE
Externí odkaz: